Maristella Maggi

Dr. Maristella Maggi

University of Pavia, Pavia, Italy
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Leukemia Research
Verified
Journal Article
Closed access
JPJean Hugues Parmentier
Jean Hugues Parmentier
MMMaristella Maggi
Maristella Maggi
ETErika Tarasco
Erika Tarasco
Claudia ScottiClaudia Scotti
Claudia Scotti
VAVassilios I. Avramis
Vassilios I. Avramis
SMSteven D. Mittelman
Steven D. Mittelman

3 November 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MMMaristella Maggi
Maristella Maggi
SMSteven D. Mittelman
Steven D. Mittelman
JPJean Hugues Parmentier
Jean Hugues Parmentier
GCGiorgio Colombo
Giorgio Colombo
MMMassimiliano Meli
Massimiliano Meli
Claudia ScottiClaudia Scotti
Claudia Scotti
L-Asparaginases (ASNases) have been used as first line drugs for paediatric Acute Lymphoblastic Leukaemia (ALL) treatment for more than 40 years. Both the Escherichia coli (EcAII) and Erwinia chrysanthemi (ErAII) type II ASNases currently used in the clinics are characterized by high in vivo instability, short half-life and the requirement of several administrations to obtain a pharmacologically active concentration. Moreover, they are sensitive to proteases (cathepsin B and asparagine endopeptidase) that are over-expressed by resistant leukaemia lymphoblasts, thereby impairing drug activity and pharmacokinetics. Herein, we present the biochemical, structural and in vitro antiproliferative characterization of a new EcAII variant, N24S. The mutant shows completely preserved asparaginase and glutaminase activities, long-term storage stability, improved thermal parameters, and outstanding resistance to proteases derived from leukaemia cells. Structural analysis demonstrates a modification in the hydrogen bond network related to residue 24, while Normal Mode-based geometric Simulation and Molecular Dynamics predict a general rigidification of the monomer as compared to wild-type. These improved features render N24S a potential alternative treatment to reduce the number of drug administrations in vivo and to successfully address one of the major current challenges of ALL treatment: spontaneous, protease-dependent and immunological inactivation of ASNase.

15 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
HJHugo de Jonge
Hugo de Jonge
LILuisa Iamele
Luisa Iamele
MMMaristella Maggi
Maristella Maggi
GPGreta Pessino
Greta Pessino
Claudia ScottiClaudia Scotti
Claudia Scotti
Auto-antibodies are classically associated with autoimmune diseases, where they are an integral part of diagnostic panels. However, recent evidence is accumulating on the presence of auto-antibodies against single or selected panels of auto-antigens in many types of cancer. Auto-antibodies might initially represent an epiphenomenon derived from the inflammatory environment induced by the tumor. However, their effect on tumor evolution can be crucial, as is discussed in this paper. It has been demonstrated that some of these auto-antibodies can be used for early detection and cancer staging, as well as for monitoring of cancer regression during treatment and follow up. Interestingly, certain auto-antibodies were found to promote cancer progression and metastasis, while others contribute to the body’s defense against it. Moreover, auto-antibodies are of a polyclonal nature, which means that often several antibodies are involved in the response to a single tumor antigen. Dissection of these antibody specificities is now possible, allowing their identification at the genetic, structural, and epitope levels. In this review, we report the evidence available on the presence of auto-antibodies in the main cancer types and discuss some of the open issues that still need to be addressed by the research community.

23 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
GPGreta Pessino
Greta Pessino
Claudia ScottiClaudia Scotti
Claudia Scotti
MMMaristella Maggi
Maristella Maggi
ICImmuno-HUB Consortium
Immuno-HUB Consortium
Liver cancer, predominantly hepatocellular carcinoma (HCC), globally ranks sixth in incidence and third in cancer-related deaths. HCC risk factors include non-viral hepatitis, alcohol abuse, environmental exposures, and genetic factors. No specific genetic alterations are unequivocally linked to HCC tumorigenesis. Current standard therapies include surgical options, systemic chemotherapy, and kinase inhibitors, like sorafenib and regorafenib. Immunotherapy, targeting immune checkpoints, represents a promising avenue. FDA-approved checkpoint inhibitors, such as atezolizumab and pembrolizumab, show efficacy, and combination therapies enhance clinical responses. Despite this, the treatment of hepatocellular carcinoma (HCC) remains a challenge, as the complex tumor ecosystem and the immunosuppressive microenvironment associated with it hamper the efficacy of the available therapeutic approaches. This review explores current and advanced approaches to treat HCC, considering both known and new potential targets, especially derived from proteomic analysis, which is today considered as the most promising approach. Exploring novel strategies, this review discusses antibody drug conjugates (ADCs), chimeric antigen receptor T-cell therapy (CAR-T), and engineered antibodies. It then reports a systematic analysis of the main ligand/receptor pairs and molecular pathways reported to be overexpressed in tumor cells, highlighting their potential and limitations. Finally, it discusses TGFβ, one of the most promising targets of the HCC microenvironment.

9 February 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MMMaristella Maggi
Maristella Maggi
Laurent Roberto ChiarelliLaurent Roberto Chiarelli
Laurent Roberto Chiarelli
GVGiovanna Valentini
Giovanna Valentini
Claudia ScottiClaudia Scotti
Claudia Scotti
Bacterial L-asparaginases have been used as anti-cancer drugs for over 4 decades though presenting, along with their therapeutic efficacy, several side effects due to their bacterial origin and, seemingly, to their secondary glutaminase activity. Helicobacter pylori type II L-asparaginase possesses interesting features, among which a reduced catalytic efficiency for L-GLN, compared to the drugs presently used in therapy. In the present study, we describe some enzyme variants with catalytic and in vitro cytotoxic activities different from the wild type enzyme. Particularly, replacements on catalytic threonines (T16D and T95E) deplete the enzyme of both its catalytic activities, once more underlining the essential role of such residues. One serendipitous mutant, M121C/T169M, had a preserved efficiency vs L-asparagine but was completely unable to carry out L-glutamine hydrolysis. Interestingly, this variant did not exert any cytotoxic effect on HL-60 cells. The M121C and T169M single mutants had reduced catalytic activities (nearly 2.5- to 4-fold vs wild type enzyme, respectively). Mutant Q63E, endowed with a similar catalytic efficiency versus asparagine and halved glutaminase efficiency with respect to the wild type enzyme, was able to exert a cytotoxic effect comparable to, or higher than, the one of the wild type enzyme when similar asparaginase units were used. These findings may be relevant to determine the role of glutaminase activity of L-asparaginase in the anti-proliferative effect of the drug and to shed light on how to engineer the best asparaginase/glutaminase combination for an ever improved, patients-tailored therapy.

1 August 2012 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
EFElisa Fermo
Elisa Fermo
PBPaola Bianchi
Paola Bianchi
Laurent Roberto ChiarelliLaurent Roberto Chiarelli
Laurent Roberto Chiarelli
MMMaristella Maggi
Maristella Maggi
GMGiuseppa Maria Luana Mandarà
Giuseppa Maria Luana Mandarà
AZAlberto Zanella
Alberto Zanella